F(ab')2 molecules made from Escherichia coli produced Fab' with hinge sequences conferring increased serum survival in an animal model

Journal of Immunological Methods

Volumn 217, Issue 1-2, 1998, Pages 1-10

  Humphreys, David P ^a   Vetterlein, Olivia M ^a   Chapman, Andrew P ^a   King, David J ^a   Antoniw, Pari ^a   Suitters, Amanda J ^a   Reeks, Dominic G ^a   Parton, Ted A H ^a   King, Lloyd M ^a   Smith, Bryan J ^a   Lang, Volker ^a   Stephens, Paul E ^a  

^a UCB PHARMA   (Belgium)

Author keywords

Antibodies; Antigen binding; Escherichia coli; F(ab')2; Hinge; Serum stability

Indexed keywords

4,4' DITHIODIPYRIDINE; CYSTEINE; HUMAN IMMUNOGLOBULIN; IMMUNOGLOBULIN F(AB')2 FRAGMENT; IODINE 125; MALEIMIDE DERIVATIVE; MERCAPTAMINE; N ETHYLMALEIMIDE; SULFUR DERIVATIVE; THIOL; TROMETAMOL;

AMINO ACID COMPOSITION; AMINO ACID SEQUENCE; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ANTIBODY STRUCTURE; AREA UNDER THE CURVE; ARTICLE; CHEMICAL BOND; CHEMICAL MODIFICATION; CROSS LINKING; ESCHERICHIA COLI; GENETIC ENGINEERING; HALF LIFE TIME; HUMAN; MALE; NONHUMAN; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; PROTEIN DEGRADATION; RAT; REDUCTION; STRUCTURE ACTIVITY RELATION;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODY AFFINITY; CYSTINE; DIMERIZATION; ESCHERICHIA COLI; GENES, IMMUNOGLOBULIN; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULIN G; MALE; MICE; MOLECULAR SEQUENCE DATA; OXIDATION-REDUCTION; PROTEIN CONFORMATION; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT FUSION PROTEINS;

EID: 0032144271     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-1759(98)00061-1     Document Type: Article

References (25)

1. Angal S., King D.J., Bodmer M.W., Turner A., Lawson A.D.G., Roberts G., Pedley B., Adair J.R. A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody. Mol. Immunol. 30:1993;105.
2. 2. Proc. Natl. Acad. Sci. U.S.A. 90:1993;457.
3. Bloom J.W., Madanat M.S., Marriott D., Wong T., Chan S.Y. Intrachain disulfide bond in the core hinge region of human IgG4. Protein Sci. 6:1997;407.
4. 125I -containing acylating agent Biochem. J. 133:1973;529.
5. 2 fragments of IgG1, IgG2, and IgG4 sub-class in vivo. Int. J. Cancer. 50:1992;416.
6. Burton D.R., Woof J.M. Human antibody effector function. Adv. Immunol. 51:1992;1.
7. Carter P., Kelley R.F., Rodrigues M.L., Snedecor B., Covarrubias M., Velligan M.D., Wong W.L.T., Rowland A.M., Kotts C.E., Carver M.E., Yang M., Bourell J.H., Shepard H.M., Henner D. High level Escherichia coli expression and production of a bivalent humanized antibody fragment. Biol. Technol. 10:1992;163.
8. 2, and Fab′ in mice. Cancer Res. 46:1986;3969.
9. Ducancel F., Gillet D., Carrier A., Lajeunesse E., Ménez A., Boulain J.C. Recombinant colorimetric antibodies: construction and characterization of a bifunctional F(ab)2/alkaline phosphate conjugate produced in Escherichia coli. Biol. Technol. 11:1993;601.
10. George A.J.T., Epenetos A. Advances in antibody engineering. Expert Opin. Ther. Pat. 6:1996;441.
11. 2 antibody containing thioether-linked Fab′ fragments. J. Immunol. 139:1987;2367.
12. Harris L.J., Larson S.B., Hasel K.W., Day J., Greenwood A., McPherson A. The three-dimensional structure of an intact monoclonal antibody for canine lymphoma. Nature. 360:1992;369.
13. Humphreys D.P., Chapman A.P., Reeks D.G., Lang V., Stephens P.E. Formation of dimeric Fabs in Escherichia coli: effect of hinge size and isotype, presence of interchain disulphide bond, Fab′ expression levels, tail piece sequences and growth conditions. J. Immunol. Methods. 209:1997;193.
14. 2 and Fab fragments of humanized anti-GPIIb/IIIa monoclonal antibody in monkeys. Gen. Pharmacol. 27:1996;435.
15. King D.J., Adair J.R., Angal S., Low D.C., Proudfoot K.A., Lloyd J.C., Bodmer M.W., Yarranton G.T. Expression, purification and characterization of a mouse-human chimeric antibody and chimeric Fab′ fragment. Biochem. J. 281:1992;317.
16. King D.J., Turner A., Farnsworth A.P.H., Adair J.R., Owens R.J., Pedley B., Baldock D., Proudfoot K.A., Lawson A.D.G., Beeley N.R.A., Millar K., Millican T.A., Boyce B.A., Antoniw P., Mountain A., Begent R.H.J., Shochat D., Yarranton G.T. Improved tumour targeting with chemically cross-linked recombinant antibody fragments. Cancer Res. 54:1994;6176.
17. Lyons A., King D.J., Owens R.J., Yarranton G.T., Millican A., Whittle N.R., Adair J.R. Site-specific attachment to recombinant antibodies via introduced surface cysteine residues. Protein Eng. 3:1990;703.
18. Melton R.G. Preparation and purification of antibody-enzyme conjugates for therapeutic applications. Adv. Drug Deliv. Rev. 22:1996;289.
19. Moroder L., Hübener G., Göhring-Romani S., Göhring W., Musiol H.J., Wünsch E. Fully synthetic immunogens: I. Kinetic studies on air oxidation of the human IgG1 bis-cysteinyl fragment 225-232. Tetrahedron. 46:1990;3305.
20. Pack P., Plückthun A. Miniantibodies: use of amphipathic helices to produce functional, flexibly linked dimeric Fv fragments with high avidity in Escherichia coli. Biochemistry. 31:1992;1579.
21. Plückthun A. Mono- and bivalent antibody fragments produced in Escherichia coli: engineering, folding and antigen binding. Immunol. Rev. 130:1992;151.
22. Rheinnecker M., Hardt C., Ilag L.L., Kufer P., Gruber R., Hoess A., Lupas A., Rottenberger C., Plückthun A., Pack P. Multivalent antibody fragments with high functional affinity for a tumour-associated carbohydrate antigen. J. Immunol. 157:1996;2989.
23. 2 formation in Escherichia coli and for improved in vivo stability. J. Immunol. 12:1993;6954.
24. Speck R.R., Couto J.R., Godwin S.G., Christian R.B., Kiwan R., Ceriani R.L., Peterson J.A. Inverted Fab2s (IFab2s): engineering and expression of novel, dimeric molecules, with a molecular weight of 100,000. Mol. Immunol. 33:1996;1095.
25. Worrell N.R., Cumber A.J., Parnell G.D., Mirza A., Forrester J.A., Ross W.C.J. Effect of linkage variation on pharmacokinetics of ricin A chain-antibody conjugates in normal rats. Anti-Cancer Drug Des. 1:1986;179.